Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy
Open Access
- 29 November 2010
- Vol. 117 (9), 1917-1927
- https://doi.org/10.1002/cncr.25691
Abstract
BACKGROUND: A prospective cohort study was undertaken to develop and validate a risk model for neutropenic complications in cancer patients receiving chemotherapy. METHODS: The study population consisted of 3760 patients with common solid tumors or malignant lymphoma who were beginning a new chemotherapy regimen at 115 practice sites throughout the United States. A regression model for neutropenic complications was developed and then validated by using a random split‐sample selection process. RESULTS: No significant differences in the derivation and validation populations were observed. The risk of neutropenic complications was greatest in cycle 1 with no significant difference in predicted risk between the 2 cohorts in univariate analysis. After adjustment for cancer type and age, major independent risk factors in multivariate analysis included: prior chemotherapy, abnormal hepatic and renal function, low white blood count, chemotherapy and planned delivery ≥85%. At a predicted risk cutpoint of 10%, model test performance included: sensitivity 90%, specificity 59%, and predictive value positive and negative of 34% and 96%, respectively. Further analysis confirmed model discrimination for risk of febrile neutropenia over multiple chemotherapy cycles. CONCLUSIONS: A risk model for neutropenic complications was developed and validated in a large prospective cohort of patients who were beginning cancer chemotherapy that may guide the effective and cost‐effective use of available supportive care. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 30 references indexed in Scilit:
- A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignanciesAnnals of Oncology, 2009
- Multivariate analysis of febrile neutropenia occurrence in patients with non‐Hodgkin lymphoma: data from the INC‐EU Prospective Observational European Neutropenia StudyBritish Journal of Haematology, 2009
- The Performance of Risk Prediction ModelsBiometrical Journal, 2008
- Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic ReviewJournal of Clinical Oncology, 2007
- EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursEuropean Journal of Cancer, 2006
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapyBreast Cancer Research and Treatment, 2006
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003
- No Adjustments Are Needed for Multiple ComparisonsEpidemiology, 1990
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976